PubMed Health⌕ Search

PubMed · 2047284

Basic principles of pharmacologic action.

Abstract

Individual differences in pharmacokinetic and pharmacodynamic factors can alter a patient's response to a drug. The health care team shares responsibility for providing optimal pharmacologic interventions. Nurses, however, spend more time with patients and are more likely to focus on the patient as an individual. These factors place them in a prime position to assess the patient's response to a drug. Nurses should always consider the probability that a change in a patient's physical condition or behavior could be caused by an adverse drug effect or, conversely, that a change in physiologic status could alter the patient's response to a drug. Before administering a new drug or a medication that is prescribed on an as-needed basis, one should consider whether the patient has disease-, nutrition-, age-, genetic-, or other-related factors that might alter pharmacokinetic or pharmacodynamic parameters. Even without knowing the myriad specific side effects attributed to a drug, an initial prediction of increased risk for adverse drug effects can be made by assessing the patients. Do they have a history of adverse drug reactions? Are they obese, malnourished, dehydrated, an alcoholic, or a smoker? Do they have hepatic or renal dysfunction? Is it possible that a loss of homeostatic reserve might affect the drug response? Application of the principles of pharmacokinetics and pharmacodynamics to nursing assessment can improve the outcome of drug therapy and decrease the incidence of adverse drug effects.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D W Schwertz. 1991. Basic principles of pharmacologic action.. https://pubmed.ncbi.nlm.nih.gov/2047284/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.

In pharmacokinetics, compartment models are often used to describe the time course of blood concentration after the administration of a drug. In this article, we propose an optimal design criterion for precise estimation of parameters included in the compartment model and illustrate the non-sequential design of sampling times of blood drug concentration data in individual pharmacokinetics. The proposed optimal design criterion minimizes the determinant of the mean-squared error matrix of the parameter estimator that is quadratically approximated by the curvature array. Therefore, the proposed criterion considers the intrinsic and parameter-effects nonlinearity underlying the compartment model, and so is applicable in a pharmacokinetic experiment where the sample size of the blood drug concentration data is quite small.

Biological Availability↗

Biowaiver monographs for immediate release solid oral dosage forms: isoniazid.

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical ingredient (API) are reviewed. Isoniazid's solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), as well as its therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Isoniazid is "highly soluble" but data on its oral absorption and permeability are inconclusive, suggesting this API to be on the borderline of BCS Class I and III. For a number of excipients, an interaction with the permeability is extreme unlikely, but lactose and other deoxidizing saccharides can form condensation products with isoniazid, which may be less permeable than the free API. A biowaiver is recommended for IR solid oral drug products containing isoniazid as the sole API, provided that the test product meets the WHO requirements for "very rapidly dissolving" and contains only the excipients commonly used in isoniazid products, as listed in this article. Lactose and/or other deoxidizing saccharides containing formulations should be subjected to an in vivo BE study.

Biological Availability↗

Experimental approaches for studying uptake and action of herbal medicines.

In order to gain wider credibility, herbal medicines must go through the rigorous scientific scrutiny to which synthetic drugs are subjected, and this includes investigating their absorption, bioavailability and metabolism. This review describes approaches for determining how active compounds in herbal formulations enter the systemic circulation. To assess how bioactive molecules enter the target organs and cells, specific cell lines and organ culture models can be used, followed by in vitro models to show how they may regulate digestion, energy balance and metabolism. This could lead to a better understanding of how herbal medicines affect digestion and absorption; fundamental questions which should be answered in addition to their mechanism of action.

Biological Availability↗